AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23352429
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 vaccine (120 μg doses at 0, 1, and 6 months)
Trial: 23353804
Drug: Clinician assessment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician assessment of oral changes according to NIH criteria
Trial: 23353804
Drug: Clinician and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician and patient assessments of oral changes
Trial: 23354509
Drug: Successful CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful CPAP therapy (n = 16)
Trial: 23354509
Drug: Unsuccessful CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsuccessful CPAP therapy (n = 8)
Trial: 23355673
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 220 mg daily for 42 days
Trial: 23355673
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg daily for 42 days
Trial: 23355673
Drug: Nadroparin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 0.3 ml subcutaneously for 42 days
Trial: 23358617
Drug: Darbepoetin (DAR)
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin (DAR) 500 μg once every 2 weeks for 12 weeks
Trial: 23359181
Drug: Panitumumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (9 mg/kg) followed by Irinotecan (350 mg/m²) every 21 days
Trial: 23364011
Drug: 25(OH)D deficiency
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D deficiency (<10 ng/mL)
Trial: 23364011
Drug: 25(OH)D insufficiency
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D insufficiency (10.0-19.9 ng/mL)
Trial: 23364011
Drug: 25(OH)D sufficiency
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D sufficiency (≥20 ng/mL)
Trial: 23364320
Drug: Traditional NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional NSAID therapy
Trial: 23369458
Drug: Thymoglobulin induction
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin induction combined with early steroid reduction to 5 mg/day, low dose cyclosporine (C2 target of 600 to 800 ng/ml), and mycophenolic acid (MPA) therapy
Trial: 23369458
Drug: Historical cohort
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical cohort treated with Thymoglobulin induction, conventional doses of cyclosporine and corticosteroids
Trial: 23370599
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg nebulized iloprost
Trial: 23372266
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg ZST
Trial: 23375329
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of autologous bone marrow concentrate
Trial: 23375926
Drug: Yoga training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga training (twice-weekly 60-min sessions for 3 months)
Trial: 23377438
Drug: Regadenoson (1.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadenoson (1.44 μg/kg/h) during pVOC
Trial: 23378284
Drug: Two 30-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 30-μg doses of unadjuvanted, inactivated pH1N1 vaccine 21 days apart
Trial: 23380277
Drug: Bafetinib 240
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bafetinib 240 or 360 mg po, administered twice with a 12-hour interval
Trial: 23380715
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression model for predicting treatment resistance
Trial: 23382117
Drug: (111)In-labeled mature
RxNorm normalized name: Camphor (natural)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (111)In-labeled mature DCs with additional intradermal vaccination
Trial: 23385153
Drug: Follow-up at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up at 6 months after treatment
Trial: 23385197
Drug: Trabectedin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.5 mg/m², intravenously over 24 hours, repeated every 21 days)
Trial: 23388195
Drug: AS03-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H1N1 pandemic vaccine
Trial: 23388559
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (54 Gy in 1.8 Gy per fraction)
Trial: 23388612
Drug: Urine insulin-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine insulin-like growth factor-binding protein 7 (IGFBP7)
Trial: 23388612
Drug: Tissue inhibitor
RxNorm normalized name: Tissue inhibitor of metalloproteinases 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue inhibitor of metalloproteinases-2 (TIMP-2)
Trial: 23390496
Drug: Telbivudine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine monotherapy (600 mg once-daily)
Trial: 23390496
Drug: Telbivudine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine plus tenofovir (300 mg once-daily)
Trial: 23391200
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of GDF-15 ≥1.8 ng/ml
Trial: 23391200
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of NTproBNP (cutoff ≥2,000 pg/ml) or hsTNT (cutoff 14 pg/ml)
Trial: 23391248
Drug: Perioperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative systemic polychemotherapy including cetuximab, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) with intraperitoneal oxaliplatin
Trial: 23391616
Drug: Topotecan (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (2.3 mg/m(2)/d) and bevacizumab (15 mg/kg) combination treatment
Trial: 23392467
Drug: Atazanavir without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir without tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Trial: 23392467
Drug: Atazanavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir with tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Trial: 23393105
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (NaHCO3) at doses of 0.3, 0.6, and 1.0 mEq/kg per day
Trial: 23393105
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (NaHCO3)
Trial: 23394629
Drug: Neoadjuvant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiochemotherapy with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2
Trial: 23396491
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) nicorandil 2 mg
Trial: 23396491
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) adenosine infusion (140 μg/kg/min)
Trial: 23396491
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) adenosine
Trial: 23396557
Drug: Routine iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine iron (n=2184; 60 mg ferrous sulfate plus 400 μg of folic acid daily throughout pregnancy)
Trial: 23396557
Drug: Selective iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective iron (n=2142; screening and treatment for anaemia and daily intake of 1 mg of folic acid)
Trial: 23398660
Drug: Video capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video capsule endoscopy (Pillcam Eso2; Given Imaging)
Trial: 23401442
Drug: R-BAC (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-BAC (rituximab 375 mg/m(2) IV on day 1, bendamustine 70 mg/m(2) IV on days 2 and 3, cytarabine 800 mg/m(2) IV on days 2 to 4) every 28 days for four to six cycles
Trial: 23403253
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine at 0.25-1 mg/kg/dose for 14 days
Trial: 23403253
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine at 1.5 mg/kg/dose
Trial: 23403253
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine at 1 mg/kg/dose
Trial: 23403253
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine at 0.25-1 mg/kg/dose
Trial: 23403322
Drug: Frequent courses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent courses (three times weekly, n=23)
Trial: 23403322
Drug: Infrequent courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrequent courses (≤ 2 times weekly, n=15)
Trial: 23410147
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy for chronic hepatitis C, specific details not available.
Trial: 23411383
Drug: Second-generation EGFR
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation EGFR TKIs (e.g., afatinib, dacomitinib, XL647, AP26113, CO-1686)
Trial: 23411383
Drug: First-generation EGFR
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation EGFR TKIs (e.g., erlotinib, gefitinib)
Trial: 23411428
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (20,000 IU weekly for 12-13 weeks)
Trial: 23414587
Drug: MEK162 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 45 mg for NRAS-mutated melanoma
Trial: 23414587
Drug: MEK162 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 45 mg for BRAF-mutated melanoma
Trial: 23416850
Drug: Reduced-intensity conditioning
RxNorm normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity conditioning regimen (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression)
Trial: 23417027
Drug: Activin A-neutralizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activin A-neutralizing antibody
Trial: 23418272
Drug: Pretreatment CMV
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment CMV DNA of <18,200 (4.3 log(10)) IU/mL
Trial: 23418272
Drug: CMV load
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV load suppression <137 IU/mL (<2.1 log(10)) at days 7, 14, and 21
Trial: 23425164
Drug: Magnetic device
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic device for sphincter augmentation
Trial: 23425514
Drug: Cooled saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled saline intravenous infusions and cooled blankets (historical controls)
Trial: 23425608
Drug: Dance intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance intervention twice weekly for eight months in addition to usual school health services
Trial: 23426034
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of homocysteine (>9.85 μmol/L)
Trial: 23426034
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of homocysteine (≤6.74 μmol/L)
Trial: 23426034
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of cysteine (>309 μmol/L)
Trial: 23426034
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of cysteine (≤260 μmol/L)
Trial: 23426034
Drug: Cysteine association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine association with rectal tumors
Trial: 23426279
Drug: SAR3419 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR3419 + VXL (vincristine/dexamethasone/l-asparaginase)
Trial: 23426279
Drug: SAR3419 (protracted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR3419 (protracted therapy after VXL)
Trial: 23426943
Drug: T-Rapa cell
RxNorm normalized name: Brassica rapa pollen
DrugBank: Brassica rapa pollen (DB10942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-Rapa cell infusion at day 14 post-HCT
Trial: 23426943
Drug: T-Rapa cell
RxNorm normalized name: Brassica rapa pollen
DrugBank: Brassica rapa pollen (DB10942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-Rapa cell infusion
Trial: 23428875
Drug: PegIFNα-2a 135-180
RxNorm normalized name: peginterferon alfa-2a 0.135 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα-2a 135-180 μg/week plus RBV 200-1200 mg/day for 48 weeks
Trial: 23429725
Drug: 3'-AmNic-rEPA (4-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3'-AmNic-rEPA (4-400 μg)
Trial: 23430175
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin hydrochloride for 3 days after each monthly IVT injection.
Trial: 23430598
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT), applied twice a week
Trial: 23433846
Drug: AZD8330 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8330 (20 mg BID)
Trial: 23433846
Drug: AZD8330 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8330 (various doses)
Trial: 23436052
Drug: Conformal radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conformal radiotherapy (RT) and vandetanib (a vascular endothelial growth factor receptor 2 inhibitor)
Trial: 23439262
Drug: ABT-450/r 150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks
Trial: 23439261
Drug: Leptin treatment
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin treatment for 25.8 ± 3.7 months
Trial: 23440228
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment via antidepressant medication (n = 126; 22.2%)
Trial: 23442518
Drug: Kochujang (KCJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kochujang (KCJ) supplement (32 g/day)
Trial: 23442518
Drug: Placebo (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (32 g/day)
Trial: 23442588
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (PRV) administered in three doses with an interval of 4 to 10 weeks (28 to 70 days)
Trial: 23443507
Drug: UCN-01 65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCN-01 65 mg/m(2) with perifosine 100 mg a day
Trial: 23443507
Drug: Perifosine 150
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine 150 mg every 6 h on day 1 followed by 100 mg once a day continuously in 28-day cycles
Trial: 23443507
Drug: UCN-01 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCN-01 at three dose levels (DL1=40 mg/m(2); DL2=65 mg/m(2); DL3=90 mg/m(2))
Trial: 23443507
Drug: UCN-01 and
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: UCN-01 and perifosine combination
Trial: 23443801
Drug: Temozolomide 150
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150 mg/m(2) administered daily on a seven-day-on, seven-day-off schedule for each 28-day cycle.
Trial: 23445875
Drug: Low hepcidin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Trial: 23445875
Drug: High hepcidin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Trial: 23446180
Drug: Computer-delivered intervention
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-delivered intervention to improve health literacy and HIV medication adherence
Trial: 23447001
Drug: Carfilzomib, lenalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd)
Trial: 23451906
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of S100B and NSE levels with clinical parameters
Trial: 23454241
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil with steroid withdrawal and reduced cyclosporine A (target level 50-90 ng/ml)
Trial: 23454694
Drug: Intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fat (iv fat)
Trial: 23454694
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat (po fat)
Trial: 23454694
Drug: Intravenous endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous endotoxin (LPS)
Trial: 23456563
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg plus FOLFOX6
Trial: 23456563
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg plus reduced CapeOx (capecitabine 850 mg/m(2))
Trial: 23456745
Drug: Ofatumumab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (500 mg, 1000 mg)
Trial: 23457473
Drug: DNA prime/adenovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime/adenovirus boost malaria vaccine (3 monthly doses of DNA plasmids followed by a single boost with adenovirus vectors)
Trial: 23457473
Drug: DNA prime/adenovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime/adenovirus boost malaria vaccine
Trial: 23458624
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and intravenous omega-3 rich lipid emulsion (n-3FA)
Trial: 23459496
Drug: Atazanavir-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir-based therapy (including atazanavir, ritonavir, and emtricitabine-tenofovir)
Trial: 23459515
Drug: NKG2D/NKp30-independent bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKG2D/NKp30-independent bispecific antibody construct (CD30xCD16A)
Trial: 23465037
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 25 mg once weekly to 50 mg twice weekly
Trial: 23466307
Drug: Tremelimumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (15 mg/kg IV every 90 days until tumor progression or severe toxicity)
Trial: 23468161
Drug: Positive bacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive bacterial culture after sonication in permanent implants
Trial: 23468161
Drug: Positive bacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive bacterial culture after sonication in temporary implants
Trial: 23468307
Drug: Subcutaneous omacetaxine
RxNorm normalized name: OMACETAXINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous omacetaxine 1.25 mg/m² twice daily days 1-14 every 28 days until hematologic response, then days 1-7 every 28 days as maintenance.
Trial: 23468538
Drug: Intravascular cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular cooling after intra-arterial reperfusion therapy (IAT)
Trial: 23468941
Drug: Metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin monotherapy (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day for 16 weeks)
Trial: 23471087
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1,200 mg
Trial: 23474348
Drug: Farletuzumab with
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Farletuzumab with chemotherapy (carboplatin and taxane)